Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.

Efficient ex vivo transduction of hematopoietic stem cells (HSCs) is encumbered by differentiation which reduces engraftment. We hypothesized that inhibiting DNA methyltransferase with decitabine would block differentiation of transduced CD34+ cells under cytokine stimulation and thus improve transd...

Full description

Bibliographic Details
Main Authors: Naoya Uchida, Matthew M Hsieh, Charlotte Platner, Yogen Saunthararajah, John F Tisdale
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4121241?pdf=render
_version_ 1818214485441118208
author Naoya Uchida
Matthew M Hsieh
Charlotte Platner
Yogen Saunthararajah
John F Tisdale
author_facet Naoya Uchida
Matthew M Hsieh
Charlotte Platner
Yogen Saunthararajah
John F Tisdale
author_sort Naoya Uchida
collection DOAJ
description Efficient ex vivo transduction of hematopoietic stem cells (HSCs) is encumbered by differentiation which reduces engraftment. We hypothesized that inhibiting DNA methyltransferase with decitabine would block differentiation of transduced CD34+ cells under cytokine stimulation and thus improve transduction efficiency for engrafting HSCs. Human CD34+ cells in cytokine-containing media were treated with or without decitabine for 24 or 48 hours, and then these cells were transduced with a GFP-expressing lentiviral vector. Utilizing decitabine pre-treatment for 48 hours, we observed an equivalent percentage of successfully transduced cells (GFP-positivity) and a higher percentage of cells that retained CD34 positivity, compared to no decitabine exposure. Cell proliferation was inhibited after decitabine exposure. Similar results were observed among CD34+ cells from six different donors. Repopulating activity was evaluated by transplantation into NOD/SCID/IL2Rγnull mice and demonstrated an equivalent percentage of GFP-positivity in human cells from decitabine-treated samples and a trend for higher human cell engraftment (measured 20-24 weeks after transplantation), compared to no decitabine exposure. In conclusion, ex vivo decitabine exposure inhibits both differentiation and proliferation in transduced human CD34+ cells and modestly increases the engraftment ability in xenograft mice, while the transduction efficiency is equivalent in decitabine exposure, suggesting improvement of lentiviral transduction for HSCs.
first_indexed 2024-12-12T06:20:56Z
format Article
id doaj.art-72e12464501a4973ace3fece1286ea51
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-12T06:20:56Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-72e12464501a4973ace3fece1286ea512022-12-22T00:34:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e10402210.1371/journal.pone.0104022Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.Naoya UchidaMatthew M HsiehCharlotte PlatnerYogen SaunthararajahJohn F TisdaleEfficient ex vivo transduction of hematopoietic stem cells (HSCs) is encumbered by differentiation which reduces engraftment. We hypothesized that inhibiting DNA methyltransferase with decitabine would block differentiation of transduced CD34+ cells under cytokine stimulation and thus improve transduction efficiency for engrafting HSCs. Human CD34+ cells in cytokine-containing media were treated with or without decitabine for 24 or 48 hours, and then these cells were transduced with a GFP-expressing lentiviral vector. Utilizing decitabine pre-treatment for 48 hours, we observed an equivalent percentage of successfully transduced cells (GFP-positivity) and a higher percentage of cells that retained CD34 positivity, compared to no decitabine exposure. Cell proliferation was inhibited after decitabine exposure. Similar results were observed among CD34+ cells from six different donors. Repopulating activity was evaluated by transplantation into NOD/SCID/IL2Rγnull mice and demonstrated an equivalent percentage of GFP-positivity in human cells from decitabine-treated samples and a trend for higher human cell engraftment (measured 20-24 weeks after transplantation), compared to no decitabine exposure. In conclusion, ex vivo decitabine exposure inhibits both differentiation and proliferation in transduced human CD34+ cells and modestly increases the engraftment ability in xenograft mice, while the transduction efficiency is equivalent in decitabine exposure, suggesting improvement of lentiviral transduction for HSCs.http://europepmc.org/articles/PMC4121241?pdf=render
spellingShingle Naoya Uchida
Matthew M Hsieh
Charlotte Platner
Yogen Saunthararajah
John F Tisdale
Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.
PLoS ONE
title Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.
title_full Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.
title_fullStr Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.
title_full_unstemmed Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.
title_short Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.
title_sort decitabine suspends human cd34 cell differentiation and proliferation during lentiviral transduction
url http://europepmc.org/articles/PMC4121241?pdf=render
work_keys_str_mv AT naoyauchida decitabinesuspendshumancd34celldifferentiationandproliferationduringlentiviraltransduction
AT matthewmhsieh decitabinesuspendshumancd34celldifferentiationandproliferationduringlentiviraltransduction
AT charlotteplatner decitabinesuspendshumancd34celldifferentiationandproliferationduringlentiviraltransduction
AT yogensaunthararajah decitabinesuspendshumancd34celldifferentiationandproliferationduringlentiviraltransduction
AT johnftisdale decitabinesuspendshumancd34celldifferentiationandproliferationduringlentiviraltransduction